|
it is my understanding from the work done in the phase 2 clincal trials with dutasteride for hair loss that they went as high as 2.5 mg in a one time dose once a week. Of course they did not ever begin a phase 3 clincal trial to establish a dosing regimen. it is probably more important to take it every day for at least a month to establish a steady state. once you do this you can probably wean back abruptly. if it makes you feel more comfortable to drop a day each week rather than go to a once a week dosing immediately, then this is a personal choice that i would not argue against. the fact is that anything one does with dutasteride in the treatment of hair loss is an off label application meaning that there is no proven protocol or long term safety documentation.
Of interest is the scalp DHT level. Finasteride 5mg lowers scalp DHT levels by 38%; dutasteride 0.5mg by 54% and the dut. 2.5mg dose by 82%. This
helps explain the hair growth observations from the dutasteride study.
Serum levels should be suppressed by 70% with fin. vs 90% with dutasteride.
here is some other interesting information.
http://findarticles.com/p/articles/mi_m0PDG/is_5_4/ai_n15396470/pg_1
Effective treatment of female androgenic alopecia with dutasteride
Journal of Drugs in Dermatology, Sept-Oct, 2005 by Malgorzata Olszewska, Lidia Rudnicka
Save a personal copy of this article and quickly find it again with Furl.net. It's free! Save it.
Abstract
Dihydrotestosterone is the main molecule responsible for androgenic alopecia. Finasteride, which reduces transformation of testosterone into dihydrotestosterone and decreases dihydrotestosterone activity, is approved for treatment of androgenic alopecia in men. We describe the case of a 46-year-old woman with androgenic alopecia, non-responsive to minoxidil, who initially benefited from finasteride. Due to only limited improvement after finasteride and persisting profound psychological distress resulting from androgenic alopecia, another 5-reductase inhibitor, dutasteride, was introduced. Clinical evaluation and trichogram were applied for assessment of dutasteride efficacy in this patient. Additionally, mean hair diameter was monitored by means of computer dermoscopy. After 6 months of therapy, significant improvement was observed and after 9 months the clinical diagnosis of androgenic alopecia could no longer be made in this patient. No side effects were observed. In conclusion, theoretical data and our experience in this case show that dutasteride might develop into a true alternative in treatment of androgenic alopecia. |
|